Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + fludrocortisone is a combination of two synthetic corticosteroids. Dexamethasone is a potent glucocorticoid with strong anti-inflammatory and immunosuppressive properties, while fludrocortisone is primarily a mineralocorticoid used for its salt-retaining effects. This combination has been investigated for use in severe inflammatory conditions such as sepsis and septic shock, where corticosteroid therapy may reduce mortality and improve clinical outcomes by modulating the body's response to systemic infection. Dexamethasone acts mainly through the glucocorticoid receptor to suppress pro-inflammatory gene expression, whereas fludrocortisone acts on the mineralocorticoid receptor to promote sodium retention and maintain vascular tone[1][3][4]. The combination aims to leverage both anti-inflammatory (dexamethasone) and hemodynamic-stabilizing (fludrocortisone) effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + fludrocortisone.